evipedia.ai
← Back

PDRN for Hair Regrowth

Evidence Review created on 09/26/2026 using AI4L / Opus 5.5

Also known as: Polydeoxyribonucleotide, Polydeoxyribonucleotides, Polideribotide, Salmon DNA, Salmon Sperm DNA, Salmon PDRN, Sodium DNA, Placentex, Rejuvenex

Motivation

Polydeoxyribonucleotide (PDRN) is a purified mix of DNA fragments taken from salmon or trout sperm. For decades it has been used in Italy and South Korea to help slow-healing wounds close. It is now injected into the scalp at aesthetic clinics as a treatment for thinning hair. The idea is that its breakdown products tell nearby cells to calm inflammation and build new small blood vessels, which might give struggling hair roots more oxygen and nutrients.

Interest has grown quickly alongside other “regenerative” scalp injections, such as those made from a person’s own blood. The human hair data come from two small studies without placebo groups and a few reports using a related product with longer DNA chains, alongside laboratory work. For people who already use proven options and are looking for more, how well these injections are supported is a practical question.

This review examines what is known about these scalp injections for hair regrowth: how they are thought to work, the strength of the human evidence, the safety record from wider medical use, how treatments are delivered, and where the evidence ends.

Benefits - Risks - Protocol - Conclusion

A short list of commentary, narrative reviews and primary research that give a high-level overview of PDRN and its use for hair loss.

No relevant content on PDRN was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; these longevity-focused outlets have not covered this injectable aesthetic treatment.

Grokipedia

No dedicated Grokipedia article on polydeoxyribonucleotide (PDRN) exists.

Examine

No Examine article on PDRN exists. Examine.com focuses on dietary supplements and does not typically cover injectable prescription products such as PDRN.

ConsumerLab

No ConsumerLab article on PDRN exists. ConsumerLab tests dietary supplements and does not typically cover injectable prescription products such as PDRN.

Systematic Reviews

Systematic reviews and meta-analyses covering PDRN and related polynucleotide injections, including their safety.

No systematic review or meta-analysis addresses PDRN for hair regrowth specifically; the claimed hair effect is represented only through broader dermatology reviews that include the single scalp study, while the principal risk (injection-related harms) is represented by the safety data in these reviews.

Mechanism of Action

PDRN is a mixture of DNA fragments (50–1,500 kDa, kilodaltons, a unit of molecular size) purified from salmon or trout sperm (Squadrito et al., 2017). After injection, DNA-cutting enzymes (nucleases) break it into nucleotides and nucleosides (DNA building blocks), which act in two ways:

  • Adenosine A2A receptor activation: the fragments preferentially stimulate the A2A receptor (a cell-surface sensor for adenosine that dampens inflammation and promotes blood-vessel growth), raising VEGF (vascular endothelial growth factor, a blood-vessel growth signal) and lowering TNF-α and IL-6 (inflammatory signaling proteins).
  • Salvage pathway supply: the pieces are recycled for DNA repair and cell division in stressed tissue.

For hair, the proposed benefit is better blood supply and less low-grade inflammation around miniaturizing (shrinking) follicles. A competing reading: in dermal papilla cells (the follicle’s signaling base), adenosine’s hair-growth signal FGF-7 (fibroblast growth factor 7) runs through the A2B receptor (a related adenosine sensor), not A2A (Iino et al., 2007). PDRN also does not block DHT (dihydrotestosterone, the androgen driving pattern hair loss), and no study has shown these pathways activated inside human scalp follicles.

After intramuscular injection in healthy volunteers, blood levels peak at about 1 hour, the half-life is about 3.5 hours and bioavailability (share reaching the bloodstream) is 80–90%. PDRN is not bound to plasma proteins, distributes in proportion to tissue blood flow, is not processed by liver cytochrome P450 enzymes (the main drug-metabolizing enzymes), and is excreted mainly in urine, as summarized in a pharmacology review (Squadrito et al., 2017, review).

Historical Context & Evolution

PDRN was developed in Italy as a tissue-repair drug. Marketed by Mastelli as Placentex, it is licensed for injection and topical use in slow-healing wounds, skin ulcers and damaged connective tissue. Italian interest in nucleic-acid derivatives for hair is older: a 1994 randomized study of a topical nucleoside product, trichoriboside, reported raised cAMP (a cell-signaling messenger) and lowered ATP (the cell’s energy currency) in scalp follicles of men with pattern hair loss (Gazzani et al., 1994); it did not measure hair counts.

During the 2000s, the University of Messina group linked PDRN’s effects to the adenosine A2A receptor and ran a placebo-controlled trial in diabetic foot ulcers that roughly doubled complete healing (Squadrito et al., 2014). South Korea adopted PDRN injections for wound, joint and tendon problems, then for aesthetic “skin booster” treatments, alongside longer-chain polynucleotide fillers.

Hair use followed this regenerative reasoning and the rise of platelet-rich plasma. A Korean study in women with female pattern hair loss reported gains in hair count and thickness in 2015 (Lee et al., 2015). In the decade since, no sham-controlled (fake-injection comparison) replication has been published; the same group combined PDRN with laser or vitamin injections in 16 patients (Cho et al., 2016), and newer data come from uncontrolled series of longer-chain polynucleotide products, including one whose product was supplied by its manufacturer, PharmaResearch (Thanasarnaksorn et al., 2025). This standing reflects missing trials rather than negative ones: a well-designed trial could move it in either direction.

Expected Benefits

High 🟩 🟩 🟩

Faster Healing of Chronic Skin Wounds ⭕️ Not Central to Hair Regrowth

PDRN speeds closure of hard-to-heal wounds, its original licensed use. In a double-blind, placebo-controlled trial in 216 people with diabetic foot ulcers, eight weeks of injections doubled complete healing (Squadrito et al., 2014); a systematic review of randomized trials found faster re-epithelialization (skin resurfacing) in other wound settings (Alhussain et al., 2026). This bears on skin repair, including healing after scalp procedures such as hair transplantation, not on hair regrowth itself. The pivotal trial came from the academic group that has produced most PDRN research.

Magnitude: Complete healing at 8 weeks in 37.3% with PDRN versus 18.9% with placebo (HR, hazard ratio, the relative rate of healing, 2.20); median time to closure 30 versus 49 days (Squadrito et al., 2014).

Short-Term Relief of Knee Osteoarthritis Pain ⭕️ Not Central to Hair Regrowth

Joint injections of PDRN reduce osteoarthritis pain for a few months. A meta-analysis of five randomized trials (290 patients) comparing PDRN with hyaluronic acid injections found less pain with PDRN at one and two months, no difference at four months, and no difference in joint function (Kim et al., 2019). Three of the five trials carried a high risk of bias. This bears on joint health, not on hair.

Magnitude: Pain on a 0–10 VAS (visual analogue scale, a patient-marked pain line) was 0.97 points lower than with hyaluronic acid at 2 months, with no significant difference at 4 months (Kim et al., 2019).

Medium 🟩 🟩

Relief of Tendon and Ligament Pain ⭕️ Not Central to Hair Regrowth

PDRN injected around painful tendons and ligaments reduces pain. A meta-analysis pooling one randomized trial and three retrospective observational studies found significant pain improvement, including in shoulder rotator cuff disorders, but no change in shoulder disability scores or strength (Gwak et al., 2021). A systematic review of seven clinical studies (169 patients) across heel, elbow, Achilles and shoulder tendon disorders reported symptom improvement without adverse effects (Bizzoca et al., 2023). This bears on musculoskeletal pain, not on hair.

Magnitude: Pooled pain reduction after PDRN injection equal to 1.43 standard deviations (standardized mean difference, an effect size in standard-deviation units); no significant change in shoulder disability scores (Gwak et al., 2021).

Improved Skin Texture and Fine Wrinkles ⭕️ Not Central to Hair Regrowth

PDRN and polynucleotides, injected or applied with microneedling (tiny skin punctures from fine needles), improve wrinkle, texture and elasticity scores. In one randomized trial included in a systematic review of randomized trials, microneedling plus PDRN reduced wrinkle severity on the validated Lemperle scale more than microneedling plus PRP (Alhussain et al., 2026, systematic review). Other studies, mostly of longer-chain polynucleotide products, were small, heterogeneous and of low-to-moderate quality (Lampridou et al., 2025, systematic review). This bears on facial skin quality, not on hair.

Magnitude: In one small randomized trial, wrinkle severity on the Lemperle scale fell 57% (2.33 to 1.00) six weeks after microneedling plus PDRN, versus 36% with microneedling plus PRP; no pooled effect size exists (Alhussain et al., 2026, systematic review).

Less Scarring After Surgery ⭕️ Not Central to Hair Regrowth

PDRN injected near fresh surgical incisions reduces excess scar formation. In a randomized controlled trial of 44 patients after open thyroidectomy (surgical removal of the thyroid gland), two injections given one and two days after surgery lowered scar redness, scar height and scar symptoms compared with no treatment; the overall scar score was lower but narrowly missed statistical significance (Kim et al., 2023). No side effects were attributed to PDRN. This bears on scar quality after procedures such as hair transplantation, not on hair regrowth itself.

Magnitude: Modified Vancouver Scar Scale (a validated scar severity score) 1.62 with PDRN versus 2.50 without at 3 months, not statistically significant; the blood-vessel (redness) subscore was significantly lower, 0.48 versus 0.90 (Kim et al., 2023).

Faster Corneal Healing After Eye Surgery ⭕️ Not Central to Hair Regrowth

PDRN eye drops, a licensed Placentex form, speed repair of the eye’s surface after laser vision correction. In a randomized, double-blind, placebo-controlled trial of 60 eyes after photorefractive keratectomy (laser reshaping of the cornea, the clear front of the eye), more eyes had fully resurfaced by day 3 with PDRN, and no adverse events occurred (Lazzarotto et al., 2004). By day 7, all eyes in both groups had healed. This bears on eye-surface repair, not on hair.

Magnitude: Complete corneal re-epithelialization on day 3 in 77% of eyes with PDRN versus 61% with placebo (Lazzarotto et al., 2004).

Low 🟩

Increased Hair Count and Thickness in Pattern Hair Loss

Twelve weekly PDRN injections increased hair count and thickness on phototrichogram (magnified scalp photography) in 20 women with pattern hair loss (Lee et al., 2015). A 16-patient study, mostly men, adding laser or vitamin injections to PDRN reported similar gains (Cho et al., 2016). Neither had a placebo arm.

Magnitude: Mean hair count rose 17.9% and hair thickness 13.5% from baseline after 12 weekly sessions of PDRN alone; no placebo comparison exists (Lee et al., 2015).

Speculative 🟨

Better Blood Supply Around Follicles

PDRN promotes new blood-vessel growth and dampens inflammation in wound models (Galeano et al., 2021, review). Whether it improves blood flow around scalp follicles is unmeasured; the basis is mechanistic only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene variant is known to alter PDRN response. Variants in ADORA2A (the gene encoding the A2A receptor) are unstudied, and inherited androgen sensitivity drives pattern hair loss through a pathway PDRN does not block.
  • Baseline biomarkers: Low ferritin (the body’s iron store), thyroid dysfunction or low vitamin D can cause or worsen shedding. Correcting them likely matters more than any injection, and no biomarker is known to predict PDRN response.
  • Sex: PDRN alone was tested only in women; men made up most of one small study combining PDRN with laser or vitamin injections. Men with androgenetic alopecia (hereditary male-pattern hair loss) have stronger androgen drive, which PDRN does not target.
  • Pre-existing conditions: Data exist only for non-scarring pattern hair loss. Telogen effluvium (temporary diffuse shedding after illness or stress) often recovers on its own, mimicking benefit, while scarring alopecias destroy follicles that cannot regrow.
  • Age: No PDRN hair study reports results for older adults separately. Longer-standing loss leaves fewer living follicles to rescue, so earlier-stage thinning is the more plausible target at any age.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Injection-Site Pain, Redness, Swelling and Bruising

Scalp PDRN is delivered through dozens of small injections, and local reactions are the most common harm. A systematic review of polynucleotide injection studies, including a scalp hair-loss study, recorded localized pain, redness, swelling, itching, bruising and transient irritation, typically resolving within a week, with no severe events (Lampridou et al., 2025). Pinpoint bleeding and tenderness are expected with scalp injection. In the same review (Lampridou et al., 2025), control groups given other injections in one included study had similar reactions, so they reflect the procedure more than the compound.

Magnitude: Transient irritation in 3.7% of participants in the scalp study; other reactions were reported as mild and short-lived, without pooled rates (Lampridou et al., 2025, systematic review).

Medium 🟥 🟥

No risk reaches Medium: beyond the common injection-site reactions recorded across several trials, harms relevant to PDRN scalp use rest on case reports and case series of other scalp-injection products or on mechanistic reasoning.

Low 🟥

Paradoxical Hair Loss and Scarring at Injection Sites

Mesotherapy (many small injections into the skin) for pattern hair loss has caused new patchy hair loss with inflammatory scarring at injection sites, appearing months after uneventful sessions (El-Komy et al., 2017). Reports involve other injected products; none names PDRN.

Magnitude: Not quantified in available studies. Only case reports and case series exist, with no denominator of treated patients.

Frontal Swelling After Scalp Injections

Forehead and eyelid swelling lasting one to four days followed scalp mesotherapy in 14 reported cases, all using injected lidocaine anesthetic (Melo et al., 2022). It is linked to the procedure, not specifically to PDRN.

Magnitude: Not quantified in available studies. The only data are a retrospective case series without the number of patients treated.

Injection-Site Infection and Abscess

Each scalp puncture can carry skin bacteria into the tissue. A case series reviewing scalp mesotherapy complications notes published reports of scalp abscesses and subcutaneous necrosis (death of tissue under the skin) (Melo et al., 2022). The reports involve other injected products; none names PDRN.

Magnitude: Not quantified in available studies. Only isolated case reports exist, with no denominator of treated patients.

Speculative 🟨

Allergic Reaction to a Fish-Derived Product

Placentex labeling lists hypersensitivity (allergy) as its contraindication. Purification removes proteins; no published PDRN allergy case was found. The basis is labeling and theoretical fish antigens.

Local Immune Suppression or Tumor Support

A2A activation dampens immune responses and promotes blood-vessel growth, effects that could theoretically favor tumors. The basis is mechanistic only; no human data link PDRN to cancer.

Risk-Modifying Factors

  • Genetic polymorphisms: No gene variant is known to change PDRN safety. Inherited bleeding disorders such as von Willebrand disease (a clotting-protein deficiency) raise bruising and bleeding risk from multiple scalp punctures.
  • Baseline biomarkers: A low platelet count or an INR (international normalized ratio, a clotting-time measure) above target range increases bruising and hematoma (a blood pocket under the skin) after injections.
  • Sex: No sex difference in reactions is reported. Pregnancy and breastfeeding lack data, and the Placentex leaflet notes limited or no pregnancy data, which is relevant for women of reproductive age.
  • Pre-existing conditions: Fish allergy, keloid tendency (raised overgrown scars), active scalp infection, flaring psoriasis or eczema, and immunosuppression (a weakened immune defense) raise the chance of allergic, scarring or infectious complications at injection sites.
  • Age: Older adults more often take anticoagulants (blood thinners) and have thinner, more fragile skin, raising bruising risk. No age-specific adverse-event data exist for PDRN.

Key Interactions & Contraindications

The Placentex prescribing information states that no formal interaction studies have been carried out. PDRN is not processed by liver drug-metabolizing enzymes, so the relevant interactions concern bleeding at injection sites and the adenosine-receptor pathway.

  • Anticoagulants (blood thinners: warfarin, apixaban, rivaroxaban): Caution. More bruising and bleeding at puncture sites. Mitigation: the prescriber confirms INR or timing; anticoagulants are not stopped without prescriber input; firm pressure after each session.
  • Antiplatelet drugs (drugs that stop platelets clumping: aspirin, clopidogrel): Caution. Increased bruising and pinpoint bleeding. Mitigation: these are typically continued when medically indicated; fine needles and post-injection pressure limit bleeding.
  • Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs: ibuprofen, naproxen): Monitor. Mildly increased bruising. Mitigation: when taken only for minor pain, clinics commonly pause them 3–7 days before sessions; acetaminophen is an alternative.
  • Adenosine-receptor blockers (theophylline, aminophylline, istradefylline): Monitor. Theoretical blunting of the A2A-mediated effect; no clinical data. Mitigation: none established; concurrent use is relevant when judging response.
  • Adenosine-raising or A2A-stimulating drugs (dipyridamole, regadenoson): Monitor. Theoretical additive adenosine-receptor effect; a systemic effect at scalp doses is unlikely. Mitigation: scalp sessions are typically not scheduled on the day of regadenoson cardiac stress testing.
  • Immunosuppressants (drugs that dampen the immune system: methotrexate, cyclosporine, tofacitinib): Caution. Higher risk of injection-site infection. Mitigation: strict antisepsis and prescriber review.
  • Bleeding-prone supplements (fish oil, vitamin E, Ginkgo biloba, garlic): Monitor. Additive bruising. Mitigation: some clinics pause them 5–7 days before sessions.
  • Supplements with additive effect on the same target: No oral supplement shares PDRN’s mechanism. Caffeine supplements are adenosine-receptor blockers with theoretical opposing effect (monitor); topical adenosine products act on the same receptor family (monitor; possible additive effect).
  • Other hair interventions (PRP, minoxidil, red-light laser devices): Monitor. Additive benefit, no known harm. PRP added hair thickness over PDRN alone in one study (Lee et al., 2015). Mitigation: introducing one change at a time makes it possible to judge which is working.
  • Injected lidocaine anesthesia: Caution. Linked to frontal swelling after scalp injections. Mitigation: topical anesthetic cream is an alternative.

Populations who should avoid PDRN:

  • Known hypersensitivity to PDRN or its inactive ingredients (labeled contraindication)
  • Confirmed fish or salmon allergy, unless an allergist has assessed tolerance
  • Pregnancy and breastfeeding (no safety data)
  • Active scalp infection, open wounds, or flaring psoriasis or eczema at injection sites
  • Bleeding disorders, platelet count below 50 × 10⁹/L, or INR above the individual’s target range
  • Active scarring alopecia (lichen planopilaris, frontal fibrosing alopecia; inflammatory conditions that destroy follicles)
  • History of keloids on the scalp or forehead
  • Active skin cancer in the treatment area

Risk Mitigation Strategies

  • Fine needles and shallow depth: 30–33 gauge needles placed about 1–2 mm deep and roughly 1 cm apart reduce pain, bleeding and bruising from injection-site trauma.
  • Topical anesthesia instead of injected lidocaine: Anesthetic cream applied 20–30 minutes beforehand and a 10-minute cold compress afterward limit pain and the frontal swelling linked to injected lidocaine.
  • Aseptic technique: Chlorhexidine or alcohol scalp preparation, sterile single-use vials, and no hair washing for 12–24 hours reduce the risk of injection-site infection and abscess.
  • Bleeding-risk review: Listing anticoagulants, antiplatelets and bleeding-prone supplements before each course, with prescriber-confirmed INR for warfarin users, reduces bruising and hematoma.
  • Allergy screen and observation: Confirming no fish allergy and observing for 15–30 minutes after the first session catches hypersensitivity reactions early.
  • Stop at new patchy loss: Any new bald patch or scarring at injection sites prompts stopping treatment and a dermatologist review with trichoscopy (magnified scalp examination) or biopsy, limiting paradoxical scarring hair loss.
  • Regulated products only: Using registered pharmaceutical or CE-marked (European medical-device conformity) products avoids contamination and mislabeling from grey-market vials.

Therapeutic Protocol

  • Trial protocol (Lee and Cho group, Korea): 2 mL of PDRN across frontal, mid and vertex (crown) scalp, weekly for 12 sessions (Lee et al., 2015), later combined with laser (Cho et al., 2016). No other PDRN hair schedule exists.
  • PRP plus PDRN (competing approach): One PRP session followed by 12 weekly PDRN sessions; the combination gave greater hair thickness than PDRN alone, but not higher hair counts (Lee et al., 2015).
  • Longer-chain polynucleotide course (Thai group): Four injection sessions at four-week intervals of a PharmaResearch polynucleotide product, used in androgenetic alopecia (Thanasarnaksorn et al., 2025). Evidence comes from an uncontrolled series.
  • Clinic course: Korean and UK aesthetic clinics commonly give 4–6 sessions spaced 2–4 weeks apart, then maintenance every 1–3 months. No published source credits this schedule to a named clinic or expert, and trials have not tested it.
  • Conventional drug approach: Topical minoxidil and, in men, finasteride (a drug lowering DHT) rest on multiple randomized trials (Adil & Godwin, 2017, meta-analysis). PDRN is used either alone or layered onto these; head-to-head comparisons do not exist.
  • Topical and microneedling route: Cosmetic PDRN ampoules applied with microneedling are marketed for scalp use by Korean cosmetic brands rather than a named clinic or expert. Large DNA fragments penetrate skin poorly, and no hair study has tested this route.
  • Time of day: Pharmacologically irrelevant for an in-clinic procedure. Clinics typically schedule sessions when the scalp can stay unwashed for 12–24 hours and strenuous exercise can be skipped.
  • Half-life: About 3.5 hours in blood after intramuscular injection, but receptor-driven tissue effects last days, which is why sessions are spaced weekly to monthly rather than daily.
  • Single versus split dosing: Each session is a single total volume, spread as many small injections roughly 1 cm apart across thinning areas; doses are not split across the day.
  • Genetic factors: No gene-based dose adjustment exists. Strongly inherited, androgen-driven loss is unlikely to be controlled by PDRN alone, so an androgen-blocking base therapy remains relevant.
  • Sex: PDRN alone was tested only in women; men appear in one small PDRN-plus-laser study and in polynucleotide series, and more often combine injections with finasteride. Women of reproductive age face absent pregnancy data.
  • Age: No dose or schedule change is established for older adults. More advanced loss at older ages leaves fewer follicles to respond, and anticoagulant use is more common.
  • Baseline biomarkers: Iron deficiency, thyroid dysfunction and low vitamin D are treatable causes of shedding; when uncorrected, they can confound any apparent response to PDRN.
  • Pre-existing conditions: Only non-scarring pattern hair loss has been studied. Telogen effluvium, alopecia areata (autoimmune patchy hair loss) and scarring alopecias lack PDRN data.

Discontinuation & Cycling

  • Short-term course, ongoing condition: PDRN is given as a finite course, but pattern hair loss is lifelong and progressive, so gains are expected to fade after stopping unless maintained. No study has measured durability.
  • Withdrawal effects: None are known. According to its prescribing information, PDRN causes no dependence or habituation, and no rebound shedding has been reported.
  • Tapering: Not required. Clinics that use maintenance simply lengthen intervals between sessions, for example from monthly to every three months.
  • Cycling: The Placentex label describes 15–20 day injection cycles that can be repeated. For hair, repeated courses with maintenance sessions are practiced, but whether cycling preserves efficacy is untested.
  • Relation to other treatments: PDRN and other hair treatments are stopped independently; ending a PDRN course does not require stopping minoxidil, finasteride or PRP.

Sourcing and Quality

  • Pharmaceutical-grade source: Registered PDRN, such as Placentex (Mastelli, Italy) and PharmaResearch products (Korea), is purified from salmon or trout sperm DNA to over 95% purity with inactivated proteins, in sterile single-use ampoules.
  • What to look for: A stated fish-sperm source, a molecular-weight range (about 50–1,500 kDa), sterility, lot number, and registration with a drug regulator or CE marking. Independent third-party testing of injectables does not exist.
  • PDRN versus polynucleotides: Polynucleotide fillers use longer DNA chains and behave differently. Hair studies are split between the two, so a product label that states which one it contains links it to the relevant evidence.
  • Vegan and cosmetic “PDRN”: Plant- or microbe-derived “PDRN” and topical cosmetic ampoules are different materials at far lower doses; none has been tested for hair regrowth.
  • Grey-market imports: Injectables bought online or imported without registration risk contamination, counterfeits and incorrect concentration. Compounding pharmacies do not typically prepare PDRN.

Practical Considerations

  • Time to effect: Both PDRN hair studies measured results after 12 weekly sessions; a polynucleotide series saw shaft diameter change within one month (Thanasarnaksorn et al., 2025). Because hair cycles are slow, visible density change is usually judged at 3–6 months.
  • Common pitfalls: Confusing PDRN with polynucleotides or cosmetic “PDRN”; dropping proven treatments; judging results by week-to-week shedding; and treating scarring or autoimmune hair loss that has no supporting data.
  • Regulatory status: Not approved by the FDA (US Food and Drug Administration). In Italy and Korea it is registered for wounds and tissue repair, not hair; scalp use is off-label everywhere.
  • Cost and access: Courses are self-paid, multi-session and clinic-based; the Italian drug itself is inexpensive, so procedure fees dominate. Insurers rarely pay for any cosmetic hair treatment, so payers have little systematic incentive favoring one option.
  • Conflicts of interest: Several PDRN and polynucleotide reviews are written by staff of regenerative-product manufacturers (Ferro et al., 2026), and both PDRN hair studies come from a single research group. Independent replication of hair findings is lacking.

Interaction with Foundational Habits

  • Sleep: None known (direct). PDRN has no reported effect on sleep; adenosine signaling in the brain regulates sleepiness, but scalp doses produce no measurable systemic effect. Adequate sleep supports recovery from injection-site bruising and swelling.
  • Nutrition: Indirect. Adequate protein, iron, zinc and vitamin D underpin hair growth that PDRN cannot replace. Caffeine blocks adenosine receptors and could theoretically blunt effects; no study confirms this. Avoiding alcohol for 24 hours around sessions reduces bruising.
  • Exercise: Indirect. Strenuous exercise, heavy sweating and saunas are avoided for 24 hours after sessions to limit swelling and infection at puncture sites. No study links exercise to better PDRN response.
  • Stress management: Indirect. Psychological stress can trigger telogen effluvium, which masks or mimics treatment effects. PDRN has no known effect on cortisol (the main stress hormone). Anxiety about injections can be eased with topical anesthetic.

Monitoring Protocol & Defining Success

Before starting, baseline testing documents the hair-loss type and rules out treatable causes. It includes standardized scalp photographs, trichoscopy measuring hair density and shaft diameter at marked sites, and blood tests: ferritin, TSH (thyroid-stimulating hormone, a thyroid function screen), 25-hydroxyvitamin D and a CBC (complete blood count, including platelets). Women with irregular periods or acne may add androgen testing. For people taking warfarin, baseline testing includes a recent INR.

Ongoing monitoring repeats photographs and trichoscopy at the same sites at 12 weeks, 24 weeks, then every 6 months while treatment continues. Blood tests are repeated every 6–12 months only if a baseline value was abnormal. Success is defined as stable or increased density and diameter compared with each person’s own baseline at 24 weeks, with no new patchy loss or scarring.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Ferritin 70–150 ng/mL Iron stores support hair growth Conventional range starts near 15–30 ng/mL; rises with inflammation, so pair with CRP (C-reactive protein, an inflammation marker)
TSH 1.0–2.5 mIU/L Thyroid dysfunction causes shedding Conventional range about 0.4–4.5 mIU/L; morning draw; biotin supplements distort results, so pause them 2–3 days before
25-hydroxyvitamin D 40–60 ng/mL Low levels are linked to hair loss Conventional sufficiency threshold 30 ng/mL; recheck 3 months after correction
Platelet count (CBC) 150–400 × 10⁹/L Bleeding risk from scalp injections Same as conventional range; below 50 × 10⁹/L avoid injections
Hair density (trichoscopy) No established target; track change from own baseline Primary efficacy measure Same marked sites, magnification and lighting each time; hair unwashed state kept consistent
Hair shaft diameter (trichoscopy) No established target; track change from own baseline Thickening often precedes density gain Share of thick hairs is more sensitive than total count in pattern hair loss

Qualitative markers:

  • Less hair in the shower drain, brush and pillow
  • Better scalp coverage in standardized photographs and in overhead lighting
  • Hair perceived as thicker or fuller when styling
  • Satisfaction with appearance and reduced worry about hair
  • Tolerability of sessions, including pain and recovery time

Emerging Research

  • No registered hair trials: A ClinicalTrials.gov search (September 2026) for PDRN and polynucleotide interventions found no study in any hair-loss condition, so no controlled hair data are expected soon.
  • PDRN with laser scar remodeling: A randomized phase 2 (early efficacy-testing) trial (NCT07472192) of 36 participants tests fractional CO₂ (carbon dioxide) laser with versus without PDRN for facial scars; primary endpoint is the Vancouver Scar Scale. It probes the repair effect proposed for follicles.
  • PDRN in acne-scar subcision: A split-face (each side of the face treated differently) randomized trial (NCT07547956) of 20 participants compares PDRN with non-cross-linked hyaluronic acid injected after subcision (cutting scar tethers under the skin); endpoints are scar topography and a scar severity score.
  • Injection versus microneedling: A 25-participant randomized trial (NCT07280637) compares PDRN-containing solution delivered by needle injection or microneedling for periocular (around-the-eye) wrinkles, with wrinkle severity as primary endpoint, informing whether microneedling delivers PDRN as well as injection.
  • Replicating the hair studies: The uncontrolled gains reported by Lee et al., 2015 and Cho et al., 2016 await a sham-controlled trial of roughly 100 or more participants, ideally with a topical minoxidil comparator, at least 24 weeks and blinded phototrichogram; such a trial could confirm or overturn them.
  • Adenosine pathway work: A topical adenosine complex increased hair thickness 10.32% over four months and inhibited androgen-receptor signaling in dermal papilla cells (Kim et al., 2024), strengthening the rationale; A2B rather than A2A dependence could weaken it.
  • Evidence that could weaken the case: A systematic review of scalp injectables for androgenetic alopecia found small, heterogeneous studies and reported paradoxical alopecia and scarring (Beer et al., 2026), harms any PDRN scalp program shares.
  • Naming and standardization: A proposed 1,500 kDa cutoff separating PDRN from polynucleotides (Marques et al., 2025), from authors employed by regenerative-product manufacturers, would clarify which product each hair study actually tested.

Conclusion

Polydeoxyribonucleotide injections use purified fragments of salmon DNA, a medicine long used in Italy and South Korea to help stubborn wounds heal. Clinics now inject it into the scalp hoping that better blood supply and calmer inflammation will revive thinning hair.

For regrowth itself, the evidence is thin. A single small study in women reported more and thicker hairs after weekly injections, but it had no comparison group given a placebo, and it has not been repeated since. Reports using a related product with longer DNA chains point the same way, yet also lack comparison groups. The strongest evidence for the compound concerns wound healing and joint pain, not hair. How it might act on hair roots rests on laboratory reasoning, part of which is disputed.

Safety looks favorable. Across decades of medical use, reported problems are mostly short-lived pain, redness and bruising from the injections. Rarer harms, such as patchy scarring hair loss, have been reported with scalp injection treatments in general rather than with this compound specifically.

The evidence base is small: both hair studies of the compound come from a single research group, and some reviews and studies are linked to manufacturers, which tempers the weight of the positive results. For health-focused adults already using established hair treatments, these injections remain an unproven add-on with a low apparent risk, a real cost in time and money, and an open question about whether they add anything meaningful.

Top - Benefits - Risks - Protocol